Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

MA Lantinga; HMA D'Agnolo; NF Casteleijn; JW de Fijter; E Meijer; AL Messchendorp; DJM Peters; Mahdi Salih; EM Spithoven; D Soonawala; FW Visser; JFM Wetzels; R. Zietse; JPH Drenth; RT Gansevoort

doi:10.1007/s40264-016-0486-x

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

MA Lantinga, HMA D'Agnolo, NF Casteleijn, JW de Fijter, E Meijer, AL Messchendorp, DJM Peters, Mahdi Salih, EM Spithoven, D Soonawala, FW Visser, JFM Wetzels, R. Zietse, JPH Drenth, RT Gansevoort

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

3 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	153-167
Number of pages	15
Journal	Drug Safety
Volume	40
Issue number	2
DOIs	https://doi.org/10.1007/s40264-016-0486-x
Publication status	Published - 2017

Access to Document

10.1007/s40264-016-0486-x

REPUB_95067-OA.pdfFinal published version, 868 KB

http://hdl.handle.net/1765/95067

Cite this

Lantinga, MA., D'Agnolo, HMA., Casteleijn, NF., de Fijter, JW., Meijer, E., Messchendorp, AL., Peters, DJM., Salih, M., Spithoven, EM., Soonawala, D., Visser, FW., Wetzels, JFM., Zietse, R., Drenth, JPH., & Gansevoort, RT. (2017). Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. Drug Safety, 40(2), 153-167. https://doi.org/10.1007/s40264-016-0486-x

@article{50e369b809ed43bc91a0453f76cafb6f,

title = "Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study",

author = "MA Lantinga and HMA D'Agnolo and NF Casteleijn and {de Fijter}, JW and E Meijer and AL Messchendorp and DJM Peters and Mahdi Salih and EM Spithoven and D Soonawala and FW Visser and JFM Wetzels and R. Zietse and JPH Drenth and RT Gansevoort",

year = "2017",

doi = "10.1007/s40264-016-0486-x",

language = "Undefined/Unknown",

volume = "40",

pages = "153--167",

journal = "Drug Safety",

issn = "0114-5916",

publisher = "Adis",

number = "2",

}

Lantinga, MA, D'Agnolo, HMA, Casteleijn, NF, de Fijter, JW, Meijer, E, Messchendorp, AL, Peters, DJM, Salih, M, Spithoven, EM, Soonawala, D, Visser, FW, Wetzels, JFM, Zietse, R, Drenth, JPH & Gansevoort, RT 2017, 'Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study', Drug Safety, vol. 40, no. 2, pp. 153-167. https://doi.org/10.1007/s40264-016-0486-x

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. / Lantinga, MA; D'Agnolo, HMA; Casteleijn, NF et al.

In: Drug Safety, Vol. 40, No. 2, 2017, p. 153-167.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

AU - Lantinga, MA

AU - D'Agnolo, HMA

AU - Casteleijn, NF

AU - de Fijter, JW

AU - Meijer, E

AU - Messchendorp, AL

AU - Peters, DJM

AU - Salih, Mahdi

AU - Spithoven, EM

AU - Soonawala, D

AU - Visser, FW

AU - Wetzels, JFM

AU - Zietse, R.

AU - Drenth, JPH

AU - Gansevoort, RT

PY - 2017

Y1 - 2017

U2 - 10.1007/s40264-016-0486-x

DO - 10.1007/s40264-016-0486-x

M3 - Article

VL - 40

SP - 153

EP - 167

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 2

ER -